Literature DB >> 29326426

mRNA vaccines - a new era in vaccinology.

Norbert Pardi1, Michael J Hogan1, Frederick W Porter2, Drew Weissman1.   

Abstract

mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in vivo delivery of mRNA. Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29326426      PMCID: PMC5906799          DOI: 10.1038/nrd.2017.243

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  214 in total

1.  Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.

Authors:  Silke Holtkamp; Sebastian Kreiter; Abderraouf Selmi; Petra Simon; Michael Koslowski; Christoph Huber; Ozlem Türeci; Ugur Sahin
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

Review 2.  The ReNAissanCe of mRNA-based cancer therapy.

Authors:  Sandra Van Lint; Dries Renmans; Katrijn Broos; Heleen Dewitte; Ine Lentacker; Carlo Heirman; Karine Breckpot; Kris Thielemans
Journal:  Expert Rev Vaccines       Date:  2014-09-29       Impact factor: 5.217

3.  Effect of thymus cell injections on germinal center formation in lymphoid tissues of nude (thymusless) mice.

Authors:  E B Jacobson; L H Caporale; G J Thorbecke
Journal:  Cell Immunol       Date:  1974-09       Impact factor: 4.868

4.  Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells.

Authors:  H J Bontkes; D Kramer; J J Ruizendaal; E W M Kueter; V F I van Tendeloo; C J L M Meijer; E Hooijberg
Journal:  Gene Ther       Date:  2006-10-12       Impact factor: 5.250

5.  Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.

Authors:  Kristen A Batich; Elizabeth A Reap; Gary E Archer; Luis Sanchez-Perez; Smita K Nair; Robert J Schmittling; Pam Norberg; Weihua Xie; James E Herndon; Patrick Healy; Roger E McLendon; Allan H Friedman; Henry S Friedman; Darell Bigner; Gordana Vlahovic; Duane A Mitchell; John H Sampson
Journal:  Clin Cancer Res       Date:  2017-04-15       Impact factor: 12.531

Review 6.  A brief history of T cell help to B cells.

Authors:  Shane Crotty
Journal:  Nat Rev Immunol       Date:  2015-02-13       Impact factor: 53.106

7.  Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients.

Authors:  Kalijn F Bol; Hanneke W Mensink; Erik H J G Aarntzen; Gerty Schreibelt; Jan E E Keunen; Pierre G Coulie; Annelies de Klein; Cornelis J A Punt; Dion Paridaens; Carl G Figdor; I Jolanda M de Vries
Journal:  Am J Ophthalmol       Date:  2014-07-17       Impact factor: 5.258

8.  mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes.

Authors:  M Mockey; E Bourseau; V Chandrashekhar; A Chaudhuri; S Lafosse; E Le Cam; V F J Quesniaux; B Ryffel; C Pichon; P Midoux
Journal:  Cancer Gene Ther       Date:  2007-06-22       Impact factor: 5.987

9.  Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.

Authors:  Hubert Kübler; Birgit Scheel; Ulrike Gnad-Vogt; Kurt Miller; Wolfgang Schultze-Seemann; Frank Vom Dorp; Giorgio Parmiani; Christian Hampel; Steffen Wedel; Lutz Trojan; Dieter Jocham; Tobias Maurer; Gerd Rippin; Mariola Fotin-Mleczek; Florian von der Mülbe; Jochen Probst; Ingmar Hoerr; Karl-Josef Kallen; Thomas Lander; Arnulf Stenzl
Journal:  J Immunother Cancer       Date:  2015-06-16       Impact factor: 13.751

10.  Horizontal transfer of RNA and proteins between cells by extracellular microvesicles: 14 years later.

Authors:  Mariusz Z Ratajczak; Janina Ratajczak
Journal:  Clin Transl Med       Date:  2016-03-04
View more
  813 in total

1.  Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling.

Authors:  Hongxia Zhang; Xinru You; Xiaojuan Wang; Lei Cui; Zining Wang; Feifei Xu; Mengyun Li; Zhenggang Yang; Jinyun Liu; Peng Huang; Yang Kang; Jun Wu; Xiaojun Xia
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

2.  Melanoma vaccines: clinical status and immune endpoints.

Authors:  Deena M Maurer; Lisa H Butterfield; Lazar Vujanovic
Journal:  Melanoma Res       Date:  2019-04       Impact factor: 3.599

Review 3.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

Review 4.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.

Authors:  Piotr S Kowalski; Arnab Rudra; Lei Miao; Daniel G Anderson
Journal:  Mol Ther       Date:  2019-02-19       Impact factor: 11.454

Review 5.  mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors:  Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-02-07       Impact factor: 11.454

6.  Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.

Authors:  Sita Awasthi; Lauren M Hook; Gokul Swaminathan; Tina M Cairns; Benjamin Brooks; Jeffrey S Smith; Noah T Ditto; Marian E Gindy; Andrew J Bett; Amy S Espeseth; Gary H Cohen; Harvey M Friedman
Journal:  Vaccine       Date:  2019-05-29       Impact factor: 3.641

Review 7.  Nanoscale platforms for messenger RNA delivery.

Authors:  Bin Li; Xinfu Zhang; Yizhou Dong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-05-04

8.  BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

Authors:  Ugur Sahin; Alexander Muik; Isabel Vogler; Evelyna Derhovanessian; Lena M Kranz; Mathias Vormehr; Jasmin Quandt; Nicole Bidmon; Alexander Ulges; Alina Baum; Kristen E Pascal; Daniel Maurus; Sebastian Brachtendorf; Verena Lörks; Julian Sikorski; Peter Koch; Rolf Hilker; Dirk Becker; Ann-Kathrin Eller; Jan Grützner; Manuel Tonigold; Carsten Boesler; Corinna Rosenbaum; Ludwig Heesen; Marie-Cristine Kühnle; Asaf Poran; Jesse Z Dong; Ulrich Luxemburger; Alexandra Kemmer-Brück; David Langer; Martin Bexon; Stefanie Bolte; Tania Palanche; Armin Schultz; Sybille Baumann; Azita J Mahiny; Gábor Boros; Jonas Reinholz; Gábor T Szabó; Katalin Karikó; Pei-Yong Shi; Camila Fontes-Garfias; John L Perez; Mark Cutler; David Cooper; Christos A Kyratsous; Philip R Dormitzer; Kathrin U Jansen; Özlem Türeci
Journal:  Nature       Date:  2021-05-27       Impact factor: 49.962

9.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

10.  Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes.

Authors:  Sita Awasthi; Lauren M Hook; Norbert Pardi; Fushan Wang; Arpita Myles; Michael P Cancro; Gary H Cohen; Drew Weissman; Harvey M Friedman
Journal:  Sci Immunol       Date:  2019-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.